Pallares, ChristianHernández-Gómez, CristhianAppel, Tobías ManuelEscandón, KevinReyes, SergioSalcedo, SorayaMatta, LorenaMartínez, ErnestoCobo, SaraMora, LauraMarín, AdrianaCorrea, AdrianaDe La Cadena, ElsaRodríguez-Baño, JesúsVillegas, María Virginia2023-05-032023-05-032022-05-02http://hdl.handle.net/10668/20271Antimicrobial stewardship programs (ASPs) have become a fundamental pillar in optimizing antimicrobial usage, improving patient care, and reducing antimicrobial resistance (AMR). Herein we evaluated the impact of an ASP on antimicrobial consumption and AMR in Colombia. We designed a retrospective observational study and measured trends in antibiotic consumption and AMR before and after the implementation of an ASP using interrupted time series analysis over a 4-year period (24 months before and 24 months after ASP implementation). ASPs were implemented according to the available resources in each of the institutions. Before ASP implementation, there was a trend toward an increase in the antibiotic consumption of all measured antimicrobials selected. Afterward, an overall decrease in antibiotic consumption was observed. The use of ertapenem and meropenem decreased in hospital wards, while a decrease in the use of ceftriaxone, cefepime, piperacillin/tazobactam, meropenem, and vancomycin was observed in intensive care units. After ASP implementation, the trend toward an increase of oxacillin-resistant Staphylococcus aureus, ceftriaxone-resistant Escherichia coli, and meropenem-resistant Pseudomonas aeruginosa was reversed. In our study, we showed that ASPs are a key strategy in tackling the emerging threat of AMR and have a positive impact on antibiotic consumption and resistance.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Antibiotic resistanceAntimicrobial resistanceAntimicrobial stewardshipAntimicrobial stewardship programColombiaHospital epidemiologyAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial StewardshipCeftriaxoneColombiaDelivery of Health CareDrug Resistance, BacterialHumansMeropenemMethicillin-Resistant Staphylococcus aureusresearch article35501756open access10.1186/s12879-022-07410-61471-2334PMC9059380https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-022-07410-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9059380/pdf